Citations

Showing 10 of 108152 citations.

Lessons learned in the surgical management of recurrent trichobezoars
Chandra, Abhishek , Rajesh, Aashish , Harvey, Lauren , Ruparel, Raaj K., Farley, David R.

Mayo Clinic

ANZ Journal of Surgery | June 14, 2021 | Volume: 92 | Issue: 1-2 | Pages: 279-282

10.1111/ans.17012 | PMID 34124843 Get It

Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient-Derived Xenografts and Direct-from-Patient Screening
Requena, David , Ramos‐Espiritu, Lavoisier , Ng, Denise , Bhola, Patrick , Jong, Ype P. de , Wang, Ruisi , Narayan, Nicole J.C., Shebl, Bassem , Michailidis, Eleftherios , Vercauteren, Koen , Hurley, Arlene , Farber, Benjamin A. , Hammond, William J. , Saltsman, James A. , Weinberg, Ethan M. , Glickman, J. Fraser , Lyons, Barbara A. , Ellison, Jessica, Schadde, Erik , Hertl, Martin, Leiting, Jennifer L. , Truty, Mark J. , Smoot, Rory L. , Tierney, Faith, Kato, Tomoaki , Wendel, Hans‐Guido , Rice, Charles M. , Letai, Anthony , Simon, Sanford M. , Requena, David , de Jong, Ype P , Michailidis, Eleftherios , Vercauteren, Koen O A , Hurley, Arlene M , Farber, Benjamin A , Hammond, William J , Glickman, J Fraser , Leiting, Jennifer L , Smoot, Rory L , LaQuaglia, Michael P , Simon, Sanford M , Weinberg, Ethan M , Lalazar, Gadi , Levin, Solomon , Kabbani, Mohammad , LaQuaglia, Michael P. , Coffino, Philip , Torbenson, Michael , Ortiz, Michael V.

Mayo Clinic

Cancer Discovery | June 14, 2021 | Volume: 11 | Issue: 10 | Pages: 2544-2563

10.1158/2159-8290.cd-20-0872 | PMID 34127480 Get It

Abstract To repurpose therapeutics for fibrolamellar carcinoma (FLC), we developed and validated patient-derived xenografts (PDX) from surgical resections. Most agents used clinically and inhibitors of oncogenes overexpressed in FLC showed little efficacy on PDX. A high-throughput functional drug screen found primary and metastatic FLC were vulnerable to clinically available inhibitors of TOPO1 and HDAC and to napabucasin. Napabucasin's efficacy was mediated through reactive oxygen species and inhibition of translation initiation, and specific inhibition of eIF4A was effective. The sensitivity of each PDX line inversely correlated with expression of the antiapoptotic protein Bcl-xL, and inhibition of Bcl-xL synergized with other drugs. Screening directly on cells dissociated from patient resections validated these results. This demonstrates that a direct functional screen on patient tumors provides therapeutically informative data within a clinically useful time frame. Identifying these novel therapeutic targets and combination therapies is an urgent need, as effective therapeutics for FLC are currently unavailable. Significance: Therapeutics informed by genomics have not yielded effective therapies for FLC. A functional screen identified TOPO1, HDAC inhibitors, and napabucasin as efficacious and synergistic with inhibition of Bcl-xL. Validation on cells dissociated directly from patient tumors demonstrates the ability for functional precision medicine in a solid tumor. This article is highlighted in the In This Issue feature, p. 2355
Faculty Opinions recommendation of First In-Human Burst Wave Lithotripsy for Kidney Stone Comminution: Initial Two Case Studies.
Humphreys, Mitchell R. , Narang, Gopal

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | June 14, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.738685997.793585856 Get It

FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice
Kommalapati, Anuhya , Tella, Sri Harsha , Javle, Milind , Mahipal, Amit , Mahipal, Amit , Kommalapati, Anuhya , Borad, Mitesh J.

Mayo Clinic

Cancers | June 14, 2021 | Volume: 13 | Issue: 12 | Pages: 2968

10.3390/cancers13122968 | PMID 34199304 Get It

Fibroblast Growth Factor receptor (FGFR) pathway aberrations have been implicated in approximately 7% of the malignancies. As our knowledge of FGFR aberrations in cancer continues to evolve, FGFR inhibitors emerged as potential targeted therapeutic agents. The promising results of pemigatinib and infigratinib in advanced unresectable cholangiocarcinoma harboring FGFR2 fusions or rearrangement, and erdafitinib in metastatic urothelial carcinoma with FGFR2 and FGFR3 genetic aberrations, lead to their accelerated approval by the United States (USA) FDA. Along with these agents, many phase II/III clinical trials are currently evaluating the use of derazantinib, infigratinib, and futibatinib either alone or in combination with immunotherapy. Despite the encouraging results seen with FGFR inhibitors, resistance mechanisms and side effect profile may limit their clinical utility. A better understanding of the unique FGFR-inhibitor-related toxicities would invariably help us in the prevention and effective management of FGFR-inhibitor-induced adverse events thereby enhancing their clinical benefit. Herein, we summarized the physiology of FGF/FGFR signaling and briefly discussed the possible mechanisms that could lead to FGFR inhibitor resistance and side effects. In addition, we proposed treatment guidelines for the management of FGFR-inhibitor-associated toxicities. This work would invariably help practicing oncologists to effectively manage the unique toxicities of FGFR inhibitors.
Pregnancy in patients with myelofibrosis: Mayo–Florence series of 24 pregnancies in 16 women
Gangat, Naseema , Guglielmelli, Paola , Al‐Kali, Aref , Wolanskyj, Alexandra P. , Camoriano, John , Patnaik, Mrinal M. , Pardanani, Animesh , Hanson, Curtis A. , Tefferi, Ayalew , Wolanskyj-Spinner, Alexandra P., Tefferi, Ayalew , Wolanskyj-Spinner, Alexandra P , Guglielmelli, Paola , Vannucchi, Alessandro M.

Mayo Clinic

British Journal of Haematology | June 14, 2021 | Volume: 195 | Issue: 1 | Pages: 133-137

10.1111/bjh.17626 | PMID 34124793 Get It

Got 15? Try Faculty Development on the Fly: A Snippets Workshop for Microlearning
Bowler, Carrie , Foshee, Cecile , Haggar, Faye L. , Schroedl, Clara , Billings, Heather , Billings, Heather , Schroedl, Clara , Billings, Heather , Bowler, Carrie A , Billings, Heather , Simpson, Deborah

Mayo Clinic

MedEdPORTAL | June 14, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.15766/mep_2374-8265.11161 | PMID 34189261 Get It

Edge-enhancing gradient echo with multi-image co-registration and averaging (EDGE-MICRA) for targeting thalamic centromedian and parafascicular nuclei
Middlebrooks, Erik H. , Okromelidze, Lela , Lin, Chen , Jain, Ayushi , Westerhold, Erin , Ritaccio, Anthony L. , Quiñones‐Hinojosa, Alfredo , Ritaccio, Anthony , Middlebrooks, Erik H , Gupta, Vivek , Grewal, Sanjeet S.

Mayo Clinic

The Neuroradiology Journal | June 14, 2021 | Volume: 34 | Issue: 6 | Pages: 667-675

10.1177/19714009211021781 | PMID 34121497 Get It

Background and purpose Deep brain stimulation of the thalamus is an effective treatment for multiple neurological disorders. The centromedian and parafascicular nuclei are recently emerging targets for multiple conditions, such as epilepsy and Tourette syndrome; however, their limited visibility on conventional magnetic resonance imaging sequences has been a major obstacle. The goal of this study was to demonstrate the feasibility of a high-resolution and high-contrast targeting sequence for centromedian-parafascicular deep brain stimulation using a recently described magnetic resonance imaging sequence, three-dimensional edge-enhancing gradient echo. Methods The three-dimensional edge-enhancing gradient echo sequence was performed on a normal volunteer for a total of six acquisitions. Multi-image co-registration and averaging was performed by first co-registering each of the six scans and then averaging to produce an edge-enhancing gradient echo-multi-image co-registration and averaging scan. The averaging was also performed for two, three, four and five scans to assess the change in the signal-to-noise ratio and identify the ideal balance of image quality and scan time. Results The edge-enhancing gradient echo-multi-image co-registration and averaging scan allowed clear boundary delineation of the centromedian and parafascicular nuclei. The signal-to-noise ratio increased as a function of increasing scan number, but the added gain was small beyond four scans for the imaging parameters used in this study. Conclusions The recently described three-dimensional edge-enhancing gradient echo sequence provides an easily implementable approach, using widely available magnetic resonance imaging technology without complex post-processing techniques, to delineate centromedian and parafascicular nuclei for deep brain stimulation targeting.
Super-Refractory Status Epilepticus in Children: A Retrospective Cohort Study
Vasquez, Alejandra , Farias‐Moeller, Raquel , Sánchez-Fernández, Iván, Amengual‐Gual, Marta , Anderson, Anne E. , Brenton, J. Nicholas , Carpenter, Jessica L. , Chapman, Kevin , Clark, Justice , Gaillard, William D. , Goldstein, Joshua , Goodkin, Howard P. , McDonough, Tiffani L. , Mikati, Mohamad A. , Morgan, Lindsey A. , Ostendorf, Adam P. , Payne, Eric T. , Peariso, Katrina , Piantino, Juan , Riviello, James J. , Sands, Tristan T. , Sannagowdara, Kumar , Tasker, Robert C. , Topjian, Alexis , Wainwright, Mark S. , Wilfong, Angus A. , Williams, Korwyn, Brenton, J Nicholas , Tasker, Robert C , Wainwright, Mark S , Gaillard, William D , Mikati, Mohamad A , Morgan, Lindsey A , Abend, Nicholas S. , Arya, Ravindra , Glauser, Tracy A. , Guerriero, Rejean M , Lai, Yi‐Chen , Novotny, Edward J. , Tchapyjnikov, Dmitry , Loddenkemper, Tobias

Mayo Clinic

Pediatric Critical Care Medicine | June 14, 2021 | Volume: 22 | Issue: 12 | Pages: e613-e625

10.1097/pcc.0000000000002786 | PMID 34120133 Get It

OBJECTIVES: To characterize the pediatric super-refractory status epilepticus population by describing treatment variability in super-refractory status epilepticus patients and comparing relevant clinical characteristics, including outcomes, between super-refractory status epilepticus, and nonsuper-refractory status epilepticus patients. DESIGN: Retrospective cohort study with prospectively collected data between June 2011 and January 2019. SETTING: Seventeen academic hospitals in the United States. PATIENTS: We included patients 1 month to 21 years old presenting with convulsive refractory status epilepticus. We defined super-refractory status epilepticus as continuous or intermittent seizures lasting greater than or equal to 24 hours following initiation of continuous infusion and divided the cohort into super-refractory status epilepticus and nonsuper-refractory status epilepticus groups. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: We identified 281 patients (157 males) with a median age of 4.1 years (1.3–9.5 yr), including 31 super-refractory status epilepticus patients. Compared with nonsuper-refractory status epilepticus group, super-refractory status epilepticus patients had delayed initiation of first nonbenzodiazepine-antiseizure medication (149 min [55–491.5 min] vs 62 min [33.3–120.8 min]; p = 0.030) and of continuous infusion (495 min [177.5–1,255 min] vs 150 min [90–318.5 min]; p = 0.003); prolonged seizure duration (120 hr [58–368 hr] vs 3 hr [1.4–5.9 hr]; p < 0.001) and length of ICU stay (17 d [9.5–40 d] vs [1.8–8.8 d]; p < 0.001); more medical complications (18/31 [58.1%] vs 55/250 [22.2%] patients; p < 0.001); lower return to baseline function (7/31 [22.6%] vs 182/250 [73.4%] patients; p < 0.001); and higher mortality (4/31 [12.9%] vs 5/250 [2%]; p = 0.010). Within the super-refractory status epilepticus group, status epilepticus resolution was attained with a single continuous infusion in 15 of 31 patients (48.4%), two in 10 of 31 (32.3%), and three or more in six of 31 (19.4%). Most super-refractory status epilepticus patients (30/31, 96.8%) received midazolam as first choice. About 17 of 31 patients (54.8%) received additional treatments. CONCLUSIONS: Super-refractory status epilepticus patients had delayed initiation of nonbenzodiazepine antiseizure medication treatment, higher number of medical complications and mortality, and lower return to neurologic baseline than nonsuper-refractory status epilepticus patients, although these associations were not adjusted for potential confounders. Treatment approaches following the first continuous infusion were heterogeneous, reflecting limited information to guide clinical decision-making in super-refractory status epilepticus.
Natural History of Growing Sporadic Vestibular Schwannomas During Observation: An International Multi-Institutional Study
Marinelli, John P. , Carlson, Matthew L. , Nassiri, Ashley M. , Haynes, David S. , Link, Michael J. , Lohse, Christine M. , Reznitsky, Martin , Stangerup, Sven‐Eric, Cayé‐Thomasen, Per , Hunter, Jacob B.

Mayo Clinic

Otology & Neurotology | June 13, 2021 | Volume: 42 | Issue: 8 | Pages: e1118-e1124

10.1097/mao.0000000000003224 | PMID 34121081 Get It

Objective: Active treatment of small- or medium-sized vestibular schwannoma during wait-and-scan management is currently recommended at most centers globally once growth is detected. The primary aim of the current study was to characterize the natural history of growing sporadic vestibular schwannoma during observation. Study Design: Cohort study. Setting: Four tertiary referral centers across the United States and Denmark. Patients: Patients with two prior MRI scans demonstrating ≥2 mm of linear growth who continued observational management. Intervention: Observation with serial imaging. Main Outcome Measure: Subsequent linear growth-free survival (i.e., an additional ≥2 mm of growth) following initial growth of ≥2 mm from tumor size at diagnosis. Results: Among 3,402 patients undergoing observation, 592 met inclusion criteria. Median age at initial growth was 66 years (IQR 59–73) for intracanalicular tumors (N = 65) and 62 years (IQR 54–70) for tumors with cerebellopontine angle extension (N = 527). The median duration of MRI surveillance following initial detection of tumor growth was 5.2 years (IQR 2.4–6.9) for intracanalicular tumors and 1.0 year (IQR 1.0–3.3) for cerebellopontine angle tumors. For intracanalicular tumors, subsequent growth-free survival rates (95% CI; number still at risk) at 1, 2, 3, 4, and 5 years following the initial MRI that demonstrated growth were 77% (67–88; 49), 53% (42–67; 31), 46% (35–60; 23), 34% (24–49; 17), and 32% (22–47; 13), respectively. For cerebellopontine angle tumors, subsequent growth-free survival rates were 72% (68–76; 450), 47% (42–52; 258), 32% (28–38; 139), 26% (21–31; 82), and 22% (18–28; 57), respectively. For every 1 mm increase in magnitude of growth from diagnosis to tumor size at detection of initial growth, the HRs associated with subsequent growth were 1.64 (95% CI 1.25–2.15; p < 0.001) for intracanalicular tumors and 1.08 (95% CI 1.01–1.15; p = 0.02) for cerebellopontine angle tumors. Conclusions: Growth detected during observation does not necessarily portend future growth, especially for slowly growing tumors. Because early treatment does not confer improved long-term quality of life outcomes, toleration of some growth during observation is justifiable in appropriately selected cases.